Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial

This randomized, placebo-controlled, cross-over, double-blind study aimed to investigate the effects of high dose, short-term (5 weeks) treatment with liraglutide in obese patients with no overt type 2 diabetes on the levels of circulating metabolites and detailed lipid profile.

Several cardiometabolic markers were affected by varying degree. Treatment of obese patients without overt type 2 diabetes with liraglutide induced changes in lipid and hormonal profiles that are suggestive of lower risk of atherosclerosis and cardiovascular disease.